Your browser doesn't support javascript.
loading
Epicardial standalone left atrial appendage clipping for prevention of ischemic stroke in patients with atrial fibrillation contraindicated for oral anticaogulation.
Branzoli, Stefano; Marini, Massimiliano; Guarracini, Fabrizio; Pederzolli, Carlo; Pomarolli, Claudio; D'Onghia, Giovanni; Centonze, Maurizio; Fantinel, Mauro; Corsini, Francesco; Bonmassari, Roberto; Graffigna, Angelo; La Meir, Mark.
Afiliação
  • Branzoli S; Cardiac Surgery Unit, Santa Chira Hospital, Trento, Italy.
  • Marini M; Department of Cardiology, Santa Chiara Hospital, Trento, Italy.
  • Guarracini F; Department of Cardiology, Santa Chiara Hospital, Trento, Italy.
  • Pederzolli C; Cardiac Surgery Unit, Santa Chira Hospital, Trento, Italy.
  • Pomarolli C; Department of Anesthesiology, Santa Chiara Hospital, Trento, Italy.
  • D'Onghia G; Department of Cardiology, Santa Chiara Hospital, Trento, Italy.
  • Centonze M; Department of Radiology, San Lorenzo Hospital, Trento, Italy.
  • Fantinel M; Department of Cardiology, Santa Maria Hospital, Feltre, Italy.
  • Corsini F; Neurosurgery Unit, Santa Chiara Hospital, Trento, Italy.
  • Bonmassari R; Department of Cardiology, Santa Chiara Hospital, Trento, Italy.
  • Graffigna A; Cardiac Surgery Unit, Santa Chira Hospital, Trento, Italy.
  • La Meir M; Department of Cardiac Surgery, UZ Brussel, Brussels, Belgium.
J Cardiovasc Electrophysiol ; 31(8): 2187-2191, 2020 Aug.
Article em En | MEDLINE | ID: mdl-32495408
INTRODUCTION: The most appropriate treatment for stroke prevention in standalone atrial fibrillation patients with a high CHADS2VASC score contraindicated for oral anticoagulation (OAC) or novel OAC (NOAC) still needs to be defined. Percutaneous left atrial appendage (LAA) closure devices are available, but because of their endocardial positioning need a period of antiplatelet therapy (APT). This study aimed to evaluate the safety and efficacy of epicardial left atrial appendage clipping in patients contraindicated for (N)OAC and APT. METHODS AND RESULTS: We describe a standalone totally thoracoscopic LAA clipping of forty-five consecutive patients with nonvalvular atrial fibrillation (NVAF; 32 males; age, 73.1 ± 7.4 years; CHADVASC, 6.5 ± 1.1; HAS-BLED 4.9 ± 0.9) with absolute contraindications to (N)OAC. The patients were selected by a multidisciplinary Heart Team. Sixty percent had a previous ischemic stroke and 51% a history of the hemorrhagic event and 22% both. All patients were implanted with an LAA epicardial clip, guided by preoperative computed tomography and intraoperative transesophageal echocardiography. The mean procedural duration was 52.3 ± 12.6 minutes with postprocedural extubation interval of 22.8 ± 14.6 minutes. No procedure-related complications occurred. Intraprocedural transesophageal echocardiography (TEE) showed complete LAA occlusion in all patients. At a mean follow-up of 16.4 ± 9.1 months (range, 2-34), with all patients off (N)OAC or APT, no ischemic stroke or hemorrhagic complications occurred. computed tomography or TEE at follow-up demonstrated a correct LAA occlusion in all with mean stumps of 3.3 ± 2.8 mm. CONCLUSION: Thoracoscopic epicardial closure of the LAA with the AtriClip PRO2 device is a potentially safe and efficient treatment for stroke prevention in patients with NVAF contraindicated for anticoagulant therapy or APT.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Isquemia Encefálica / Apêndice Atrial / Acidente Vascular Cerebral / AVC Isquêmico Tipo de estudo: Diagnostic_studies / Etiology_studies Limite: Aged / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Isquemia Encefálica / Apêndice Atrial / Acidente Vascular Cerebral / AVC Isquêmico Tipo de estudo: Diagnostic_studies / Etiology_studies Limite: Aged / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article